Pregnancy outcomes with chronic hypertetion on different antihypertensive therapy

Status

Active, not recruiting

Phases

Phase 2

Study type

Interventional

Source

IRCT

Registry ID

IRCT201602067676N5

Enrollment

Registered

2016-02-23

Start date

2016-02-15

Completion date

Unknown

Last updated

2018-02-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Preeclampsia. Gestational [pregnancy-induced] hypertension

Interventions

Intervention 1: methyldopa 250 mg b.i.d 4g/d. Intervention 2: Hydralazine 5-10 mg iv every 20 min 30 mg. Intervention 3: Nifidipine 10mg b.i.d. Intervention 4: diltiazem 120-180 mg q.d.

Treatment - Drugs

methyldopa 250 mg b.i.d 4g/d

Hydralazine 5-10 mg iv every 20 min 30 mg

Nifidipine 10mg b.i.d

diltiazem 120-180 mg q.d

Eligibility

Sex/Gender

Female

Inclusion criteria

Inclusion criteria: Inclusion criterion: pregnant women with chronic hypertension. Exclusion criteria: absence of consent to participate.

Exclusion criteria

Exclusion criteria:

Design outcomes

Primary

Measure	Time frame
Added preeclampsia. Timepoint: During prenatal visits. Method of measurement: Manometer.	—

Secondary

Measure	Time frame
Placental abruption. Timepoint: During pregnancy. Method of measurement: Physical examination.;Fetal death. Timepoint: During pregnancy. Method of measurement: Ultrasound.;Acute kidney injury. Timepoint: During pregnancy. Method of measurement: Physical examination.;Cerebral hemorrhage. Timepoint: During pregnancy. Method of measurement: Physical examination.	—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactDr. Simin Taghavi

Tabriz University of Medical Sciences

lahroudin@gmail.com+98 914 115 6248

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026